# Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

> **NCT04585477** · PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 80 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage I
- Non-small Cell Lung Cancer Stage II
- Non-small Cell Lung Cancer Stage III

## Interventions

- **DEVICE:** AVENIO ctDNA Surveillance Kit
- **DRUG:** Durvalumab
- **DRUG:** Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy

## Key facts

- **NCT ID:** NCT04585477
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-08
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585477, "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04585477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*